Get the SPI Wire

iBio, Inc.

NASDAQ:IBIO
Annual Meeting

of Shareholders

MEETING DATE

10/14/2026
DEF 14A FILED
09/04/2026
PUBLISHED
09/04/2026 8:05 pm
TIME TO PUBLISH
09/06/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:IBIO · CUSIP 451033708 · CLASS common stock, $0.001 par value per share · CIK 0001420720

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
1
AGAINST
0
WITHHOLD
6
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Election of two (2) Class III directors
board
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

Each nominee agreed to serve if elected.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Ratification of the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for the fiscal year ending on June 30, 2027
auditor
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states there were no disagreements or reportable events with Grassi during fiscal 2026 and 2025.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approval, on an advisory, non-binding basis, of the compensation of our named executive officers (Say-on-Pay)
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

Approximately 92% of 2025 say-on-pay votes cast supported named executive officer compensation.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approval of an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of Common Stock to 500,000,000 shares
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

The filing states additional shares could dilute voting rights and discourage unsolicited takeover attempts.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approval of an amendment to the Company's 2023 Omnibus Incentive Plan to amend the "evergreen" provision
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

As of September 1, 2026, only 232,761 shares remained available for future issuance under the plan.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
Approval of an adjournment of the 2026 Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are not sufficient votes in favor of Proposal 4 and/or Proposal 5
other
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states adjournment would permit further solicitation if votes for Proposals 4 or 5 are insufficient.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

c60d350bc71aa03699e02e705d7c8333c4bfe3fb95b934d96ac13c7cc74067a4

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates